Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LEISH-F3 + SLA-SE
- Development stage
- Phase 1
- Lead developer
- Access to Advanced Health Institute
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
LEISH-F3 + SLA-SE is a recombinant protein subunit vaccine candidate for the prevention of leishmaniasis. The vaccine consists of the LEISH-F3 antigen—a fusion protein composed of two *Leishmania* proteins (nucleoside hydrolase [NH] and sterol 24-c-methyltransferase [SMT])—formulated with the adjuvant SLA-SE (second-generation lipid adjuvant in stable emulsion). The combination is designed to induce robust cellular and humoral immune responses against *Leishmania* species. Preclinical studies demonstrated that immunization with this formulation confers protection in animal models, and phase 1 clinical trials have been conducted to assess safety and immunogenicity in healthy adults. The vaccine aims to elicit protective T cell responses, particularly Th1-type immunity, which are critical for defense against visceral leishmaniasis[1][5][3].
- Other names
- LEISH F3+SLA-SELeish F3 plus SLA-SELeishF3+SLA-SE
02
Targets
HLA-I/II (Human leukocyte antigen (HLA) class I and class II molecules)TLR4 (Toll-like receptor 4)NH36 (Leishmania nucleoside hydrolase NH36)SMT (Sterol 24-C-methyltransferase)
Beyond the preview
Go deeper on LEISH-F3 + SLA-SE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LEISH-F3 + SLA-SE.